 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
Technologiepark 4
9052 Zwijnaarde
Belgium
|
|
Portrait
ActoGeniX was founded in June 2006, as a spin-off from VIB and Ghent University, to exploit its proprietary TopAct™ platform for oral administration of biopharmaceuticals. The Company is developing a broad and diverse portfolio of novel therapeutic products addressing major diseases with high unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product has already been successfully tested in a clinical trial with Crohn’s disease patients.
Industrial Sectors
Additional information
ActoGeniX NV
Zwijnaarde, Belgium
News
|
|
|
|
|
|
Top
